We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 180

S. 8 case not struck, despite prohibition order having issued in underlying s. 6 proceeding

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • December 4 2014

In this case, the Prothonotary refused to strike a Statement of Claim brought pursuant to s. 8 of the NOC Regulations, and this decision was upheld

Leave to appeal to SCC granted for a section 8 damages case

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • November 3 2014

The Supreme Court has granted leave in a proceeding pursuant to section 8 of the PM(NOC) Regulations. Some of the issues to be decided in this

Pleadings amendment to a damages reference not allowed found to be a collateral attack on the final judgment

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • November 3 2014

Apotex moved to file an amended Responding Statement of Issues on a reference pursuant to Rule 153. According to the Court, Apotex wants to argue

Patent not eligible for listing: patent claiming one medicinal ingredient,but directed to a fixed-dose combination of medicines

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • October 15 2014

This was an appeal from two decisions for three proceedings before Prothonotary Milczynski, in which she determined that a patent could not be listed

Causes of action found against Pfizer for a BC class-action certification based on the VIAGRA patent

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • August 14 2014

Pfizer had a Canadian patent for VIAGRA that was found to not comply with the disclosure requirement by the Supreme Court in an earlier PM(NOC

The Federal Court finds two generic company's allegations to be unjustified

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 10 2014

Two PM(NOC) decisions relating to the same patent were recently released by the Federal Court. In both cases, the applications were allowed

Patent held invalid for not meeting promise of improved therapeutic profile

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 10 2014

Apotex was successful in the previous NOC Proceeding. It came to market with an esomeprazole product. AstraZeneca sued for patent infringement and

Industry news

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 10 2014

Health Canada has opened a Consultation regarding Plain Language Labelling. It is open until September 2, 2014. Health Canada has opened a

FCA refuses to stay injunction order

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 10 2014

Janssen and Abbvie were involved in a patent infringement action. Abbvie was successful in its claim for infringement, and the patent was held to be

Order of prohibition overturned on appeal

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • June 16 2014

The issue to be determined by the Court of Appeal related to whether the allegation of lack of utility was justified. The Court of Appeal began by